Randomisation of Relapsed and Refractory High-Risk Neuroblastoma Patients Treated with Long-Term Infusion of Anti-GD2 Antibody Dinutuximab Beta with or Without Subcutaneous Interleukin-2, A SIOPEN Study

被引：0
|
作者：
Lode, H. [1 ]
Valteau-Couanet, D. [2 ]
Gray, J. [3 ]
Luksch, R. [4 ]
Wieczorek, A. [5 ]
Castel, V. [6 ]
Ash, S. [7 ]
Owens, C. [8 ]
Laureys, G. [9 ]
Papadakis, V. [10 ]
Garaventa, A. [11 ]
Manzitti, C. [11 ]
Siebert, N. [1 ]
Troschke-Meurer, S. [1 ]
Glogova, E. [12 ]
Poetschger, U. [12 ]
Ladenstein, R. [12 ]
机构：
[1] Univ Med Greifswald, Pediat Hematol & Oncol, Greifswald, Germany
[2] Paris Sud Univ, Gustave Roussy, Children & Adolescent Oncol Dept, Paris, France
[3] Univ Southampton, Pediat Oncol, Southampton, Hants, England
[4] Fdn IRCCS Ist Nazl Tumori, Pediat Oncol, Milan, Italy
[5] Jagiellonian Univ, Coll Med, Pediat Hematol Oncol, Krakow, Poland
[6] Hosp Univ & Politecn La Fe, Pediat Oncol, Valencia, Spain
[7] Tel Aviv Univ, Sackler Fac Med, Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel
[8] Our Ladys Childrens Hosp Crumlin, Pediat Haematol Oncol, Dublin, Ireland
[9] Univ Hosp Ghent, Pediat Oncol, Ghent, Belgium
[10] Agia Sofia Childrens Hosp, Dept Pediat Hematol Oncol, Athens, Greece
[11] IRCCS Ist Giannina Gaslini, Oncol Unit, Genoa, Italy
[12] St Anna Kinderkrebsforsch, CCRI, Vienna, Austria
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP054 SIOP
引用
收藏
页码：S34 / S35
页数：2
相关论文
共 50 条
  • [41] Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
    Evers, Mitchell
    Stip, Marjolein
    Keller, Kaylee
    Willemen, Hanneke
    Nederend, Maaike
    Jansen, Marco
    Chan, Chilam
    Budding, Kevin
    Nierkens, Stefan
    Valerius, Thomas
    Meyer-Wentrup, Friederike
    Eijkelkamp, Niels
    Leusen, Jeanette
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [42] Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
    Cabral, Jennifer
    Fernandez, Erica, I
    Toy, Bonnie
    Secola, Rita
    PEDIATRIC DRUGS, 2023, 25 (01) : 13 - 25
  • [43] Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
    Jennifer Cabral
    Erica I. Fernandez
    Bonnie Toy
    Rita Secola
    Pediatric Drugs, 2023, 25 : 13 - 25
  • [44] Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
    Blom, Thomas
    Lurvink, Roosmarijn
    Aleven, Leonie
    Mensink, Maarten
    Wolfs, Tom
    Dierselhuis, Miranda
    van Eijkelenburg, Natasha
    Kraal, Kathelijne
    van Noesel, Max
    van Grotel, Martine
    Tytgat, Godelieve
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [45] Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).
    Ladenstein, Ruth
    Poetschger, Ulrike
    Gray, Juliet
    Valteau-Couanet, Dominique
    Luksch, Roberto
    Castel, Victoria
    Yaniv, Isaac
    Laureys, Genevieve
    Elliott, Martin
    Michon, Jean Marie
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Glogova, Evgenia
    Schreier, Guenter
    Loibner, Hans
    Lode, Holger N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
    Desai, Ami Vijay
    Fox, Elizabeth
    DiSipio, Theresa C.
    Smith, L. Mary
    Lim, Allison
    Maris, John M.
    Balis, Frank M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies
    Sun, Xiaofei
    Zhen, Zijun
    Guo, Ying
    Gao, Yuanhong
    Wang, Juan
    Zhang, Yu
    Zhu, Jia
    Lu, Suying
    Sun, Feifei
    Huang, Junting
    Cai, Ruiqing
    Zhang, Yizhuo
    Liu, Juncheng
    Xiao, Zizheng
    Zeng, Sihui
    Liu, Zhuowei
    CANCERS, 2021, 13 (14)
  • [48] Treatment-Related Toxicities During ANTI-GD2 Immunotherapy in High-Risk Neuroblastoma Patients in the Netherlands
    Blom, T.
    Lurvink, R.
    Aleven, L.
    Wolfs, T.
    Mensink, M.
    Dierselhuis, M.
    Van Eijkelenburg, N.
    Kraal, K.
    Van Noesel, M.
    Van Grotel, M.
    Tytgat, G.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S279 - S279
  • [49] Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma.
    Suzuki, Maya
    Cheung, Irene Y.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] KIR/HLA GENOTYPES PREDICTIVE OF MISSING KIR LIGANDS ARE ASSOCIATED WITH IMPROVED OUTCOME IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA TREATED WITH ANTI-GD2 MONOCLONAL ANTIBODY THERAPY
    Gallagher, Meighan
    Tarek, Nidale
    Zheng, Junting
    Venstrom, Jeffrey M.
    Cheung, Irene Y.
    Modak, Shakeel
    Dupont, Bo
    Cheung, Nai-Kong V.
    Hsu, Katharine C.
    PEDIATRIC BLOOD & CANCER, 2011, 56 (06) : 959 - 960
12345